Categories: News

First-in-Class Biologic Eye Drop Regener-Eyes(R) Announces Scholarship Winner

PALM HARBOR, FL / ACCESSWIRE / April 6, 2021 / Regener-Eyes® is pleased to announce Jenna Gardner as the recipient of the 2021 Academic Scholarship Program. After an overwhelmingly high response rate, the professionals at Regener-Eyes® feel that Jenna demonstrated both a passion for her area of study and a sophisticated understanding of regenerative medicine and its connection to eye health.

“We are proud to offer Jenna financial aid to help further her career in optometry,” stated C. Randall Harrell, M.D., CEO and Founder of Regener-Eyes®. “On behalf of the entire team, we wish her a successful academic year.”

Currently studying at the Kentucky College of Optometry, Jenna aims to gain further insight into the pharmacological aspects of eye care to better serve her local community.

In a 400-word essay, applicants were asked to explain how biologics are transforming regenerative medicine. Jenna explains how the active ingredients in Regener-Eyes® stimulate the body’s natural ability to heal:

“In the past, I often described dry eye treatments to act as band-aids only temporarily masking the problem. Now as I explore active ingredients in Regener-Eyes®, I understand how biologics could be better than tears in a variety of cases. Mimicking a normal, healthy tear film could increase the patient’s overall well-being by proactively treating before symptoms have a chance to manifest. For example, biologics containing cytokines closely associated with chronic eye inflammation that aid in cellular repair, would be invaluable for the vast number of glaucoma, diabetic retinopathy and macular edema patients. Just as hyaluronic acid would be for patients who need to hydrate the corneal surface.”

Jenna looks forward to continuing her studies as she discovers more ways to treat her community. Jenna will receive $10,000 US to be put towards her education. We captured Jenna’s reaction when she learned that she was selected as our top applicant.

The professionals at Regener-Eyes® would also like to formally thank all those who took the time to apply.

About Regener-Eyes®

Regener-Eyes® is a sterile biologic eye drop made of anti-inflammatory cytokines and growth factors. These types of proteins have been shown to reduce inflammation and stimulate the ocular surface to heal, repair, and regenerate. If you have patients that are not responding to current dry eye drugs, amniotic membrane intolerant, or having issues with blood serum tears, many physicians are finding success with Regener-Eyes® as a new option. For more information on our first in class biologic eye drop, please visit www.mydryeyes.org, follow us Instagram, like us on Facebook, watch us on YouTube and connect with us on LinkedIn.

For more information on the first-in-class biologic eye drop please visit the official site at www.mydryeyes.org.

Contact Information:

Regener-Eyes®, LLC
Heidi Hart Pukas
Heidi.pukas@regenerativeplant.org
http://regener-eyesscholarship.com/
https://www.linkedin.com/company/regener-eyes%C2%AE-llc
https://www.facebook.com/Mydryeyes

SOURCE: Regener-Eyes®

View source version on accesswire.com:
https://www.accesswire.com/639160/First-in-Class-Biologic-Eye-Drop-Regener-EyesR-Announces-Scholarship-Winner

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

23 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

24 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

27 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

27 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

27 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

27 minutes ago